Search

Author/Creator Chari, Ajai

1. A combination of carfilzomib, dexamethasone, and daratumumab for treatment of adult patients with relapsed/refractory multiple myeloma in two dosing regimens: once-weekly and twice-weekly. Issue 12 (2nd December 2021)

Authors:
Leleu, Xavier; Chari, Ajai; Richard, Shambavi; Khurana, Monica; Yusuf, Akeem; Usmani, Saad Z.
Journal:
Expert review of hematology
Issue:
Volume 14:Issue 12(2021)
Page Start:
1049
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. A comprehensive overview of daratumumab and carfilzomib and the recently approved daratumumab, carfilzomib and dexamethasone regimen in relapsed/refractory multiple myeloma. Issue 1 (2nd January 2021)

Authors:
Richard, Shambavi; Jagannath, Sundar; Cho, Hearn Jay; Parekh, Samir; Madduri, Deepu; Richter, Joshua; Chari, Ajai
Journal:
Expert review of hematology
Issue:
Volume 14:Issue 1(2021)
Page Start:
31
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end‐stage renal disease requiring haemodialysis. (16th May 2016)

Authors:
Gupta, Neeraj; Hanley, Michael J.; Harvey, R. Donald; Badros, Ashraf; Lipe, Brea; Kukreti, Vishal; Berdeja, Jesus; Yang, Huyuan; Hui, Ai‐Min; Qian, Mark; Zhang, Xiaoquan; Venkatakrishnan, Karthik; Chari, Ajai
Journal:
British journal of haematology
Issue:
Volume 174:Number 5(2016)
Page Start:
748
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. A phase 1 dose‐escalation study of filanesib plus bortezomib and dexamethasone in patients with recurrent/refractory multiple myeloma. Issue 21 (19th July 2016)

Authors:
Chari, Ajai; Htut, Myo; Zonder, Jeffrey A.; Fay, Joseph W.; Jakubowiak, Andrzej J.; Levy, Joan B.; Lau, Kenneth; Burt, Steven M.; Tunquist, Brian J.; Hilder, Brandi W.; Rush, Selena A.; Walker, Duncan H.; Ptaszynski, Mieke; Kaufman, Jonathan L.
Journal:
Cancer
Issue:
Volume 122:Issue 21(2016)
Page Start:
3327
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. A phase I study of selinexor combined with weekly carfilzomib and dexamethasone in relapsed/refractory multiple myeloma. (15th February 2023)

Authors:
Derman, Benjamin A; Chari, Ajai; Zonder, Jeffrey; Major, Ajay; Stefka, Andrew T; Jiang, Ken; Karrison, Theodore; Jasielec, Jagoda; Jakubowiak, Andrzej
Journal:
European journal of haematology
Issue:
Volume 110:Number 5(2023)
Page Start:
564
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed/refractory multiple myeloma. Issue 9 (28th July 2020)

Authors:
Van Oekelen, Oliver; Parekh, Samir; Cho, Hearn J.; Vishnuvardhan, Nivetha; Madduri, Deepu; Richter, Joshua; Ip, Chun; Lau, Kenneth; Florendo, Erika; Mancia, Ines S.; Thomas, Joanne; Verina, Daniel; Chan, Elaine; Zarychta, Katarzyna; La, Lisa; Strumolo, Gina; Melnekoff, David T.; Leshchenko, Viole...
Journal:
Leukemia & lymphoma
Issue:
Volume 61:Issue 9(2020)
Page Start:
2208
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. A Three-Gene Signature Predicts Response to Selinexor in Multiple Myeloma. (15th June 2022)

Authors:
Restrepo, Paula; Bhalla, Sherry; Ghodke-Puranik, Yogita; Aleman, Adolfo; Leshchenko, Violetta; Melnekoff, David T.; Agte, Sarita; Jiang, Joy; Madduri, Deepu; Richter, Joshua; Richard, Shambavi; Chari, Ajai; Cho, Hearn Jay; Jagannath, Sundar; Walker, Christopher J.; Landesman, Yosef; Laganà, Aless...
Journal:
JCO precision oncology
Issue:
Volume 6(2022)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Issue 2 (February 2020)

Authors:
Lonial, Sagar; Lee, Hans C; Badros, Ashraf; Trudel, Suzanne; Nooka, Ajay K; Chari, Ajai; Abdallah, Al-Ola; Callander, Natalie; Lendvai, Nikoletta; Sborov, Douglas; Suvannasankha, Attaya; Weisel, Katja; Karlin, Lionel; Libby, Edward; Arnulf, Bertrand; Facon, Thierry; Hulin, Cyrille; Kortüm, K Mart...
Journal:
Lancet oncology
Issue:
Volume 21:Issue 2(2020)
Page Start:
207
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗